Citations

Clear

40 citation(s) found for "Thomas, Scott".

Phase I double-blind, placebo-controlled trial of dolcanatide (SP-333) 27 mg to explore colorectal bioactivity in healthy volunteers
Weinberg, David S. , Foster, Nathan R. , Della’Zanna, Gary , Pallotto, Angela, Katz, Leo C., Henry, Christopher , Moleski, Stephanie , McMurray, Ryan P. , Limburg, Paul J. , Waldman, Scott A , Kraft, Walter K. , Kastenberg, David , Waldman, Scott A.

Mayo Clinic

Cancer Biology & Therapy | October 11, 2021 | Volume: 22 | Issue: 10-12 | Pages: 544-553

10.1080/15384047.2021.1967036 | PMID 34632925 Get It

Recommendations for Statistical Reporting in Cardiovascular Medicine: A Special Report From the American Heart Association
Althouse, Andrew D. , Below, Jennifer E , Claggett, Brian , Cox, Nancy J. , Lemos, James A. de , Deo, Rahul C. , Duval, Sue , Hachamovitch, Rory , Kaul, Sanjay , Keith, Scott W. , Teixeira‐Pinto, Armando , Roger, Véronique L. , Below, Jennifer E , Secemsky, Eric A.

Mayo Clinic

Circulation | May 25, 2021 | Volume: 144 | Issue: 4 | Pages: No page available

10.1161/circulationaha.121.055393 | PMID 34032474 Get It

Statistical analyses are a crucial component of the biomedical research process and are necessary to draw inferences from biomedical research data. The application of sound statistical methodology is a prerequisite for publication in the American Heart Association (AHA) journal portfolio. The objective of this document is to summarize key aspects of statistical reporting that might be most relevant to the authors, reviewers, and readership of AHA journals. The AHA Scientific Publication Committee convened a task force to inventory existing statistical standards for publication in biomedical journals and to identify approaches suitable for the AHA journal portfolio. The experts on the task force were selected by the AHA Scientific Publication Committee, who identified 12 key topics that serve as the section headers for this document. For each topic, the members of the writing group identified relevant references and evaluated them as a resource to make the standards summarized herein. Each section was independently reviewed by an expert reviewer who was not part of the task force. Expert reviewers were also permitted to comment on other sections if they chose. Differences of opinion were adjudicated by consensus. The standards presented in this report are intended to serve as a guide for high-quality reporting of statistical analyses methods and results.
Cardiopoietic Stem Cell Therapy in Ischaemic Heart Failure: Long-Term Clinical Outcomes
Behfar, Atta , Sanz‐Ruiz, Ricardo , Sherman, Warren, Heyndrickx, Guy R. , Metra, Marco , Filippatos, Gerasimos , Henry, Timothy D. , Hajjar, Roger J. , Tendera, Michał , Senger, Stefanie , Povsic, Thomas J. , Program, for the CHART, Behfar, Atta , Metra, Marco , Bartúnek, Jozef , Terzic, André , Davison, Beth A. , Wojakowski, Wojciech , Waldman, Scott A. , Teerlink, John R , Gersh, Bernard J. , Cotter, Gad , Wijns, William , Program, for the CHART

Mayo Clinic

ESC Heart Failure | October 23, 2020 | Volume: 7 | Issue: 6 | Pages: 3345-3354

10.1002/ehf2.13031 | PMID 33094909 Get It

Abstract Aims This study aims to explore long-term clinical outcomes of cardiopoiesis-guided stem cell therapy for ischaemic heart failure assessed in the Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial. Methods and results CHART-1 is a multinational, randomized, and double-blind trial conducted in 39 centres in heart failure patients (n = 315) on standard-of-care therapy. The ‘active’ group received cardiopoietic stem cells delivered intramyocardially using a retention-enhanced catheter. The ‘control’ group underwent patient-level sham procedure. Patients were followed up to 104 weeks. In the entire study population, results of the primary hierarchical composite outcome were maintained neutral at Week 52 [Mann–Whitney estimator 0.52, 95% confidence interval (CI) 0.45–0.59, P = 0.51]. Landmark analyses suggested late clinical benefit in patients with significant left ventricular enlargement receiving adequate dosing. Specifically, beyond 100 days of follow-up, patients with left ventricular end-diastolic volume of 200–370 mL treated with ≤19 injections of cardiopoietic stem cells showed reduced risk of death or cardiovascular hospitalization (hazard ratio 0.38, 95% CI 0.16–0.91, P = 0.031) and cardiovascular death or heart failure hospitalization (hazard ratio 0.28, 95% CI 0.09–0.94, P = 0.040). Cardiopoietic stem cell therapy was well tolerated long term with no difference in safety readouts compared with sham at 2 years. Conclusions Longitudinal follow-up documents that cardiopoietic stem cell therapy is overall safe, and post hoc analyses suggest benefit in an ischaemic heart failure subpopulation defined by advanced left ventricular enlargement on tolerable stem cell dosing. The long-term clinical follow-up thus offers guidance for future targeted trials.
Whole Blood for Civilian Urban Trauma Resuscitation: Historical, Present, and Future Considerations
Friès, D , Moore, Ernest E. , Moore, Hunter B. , Thomas, Scott , Kwaan, Hau C. , Marsee, Mathew, Grisoli, Anne , McCauley, Ross , Lune, Stefani Vande, Chitta, Swetha, Vyakaranam, Sudhir, Waxman, Dan A. , McCurdy, Michael T. , Zimmer, Donald , Patel, B. M. , Thachil, Jecko , Walsh, Mark M.

Mayo Clinic

Seminars in Thrombosis and Hemostasis | March 11, 2020 | Volume: 46 | Issue: 02 | Pages: 221-234

10.1055/s-0040-1702174 | PMID 32160645 Get It

AbstractWhole blood (WB) has been used for more than a century for far-forward combat resuscitation. Following the Iraq/Afghanistan combat, maritime, and austere environment use of WB for the resuscitation of severely hemorrhaging patients, there has been an increasing use of WB for the civilian urban resuscitation environment population. The impetus for this was not just improved outcomes in far-forward hospitals, which had different populations and different needs than the civilian urban population, but also an application of the lessons suggested by recent 1:1:1 plasma:platelets:packed red cells fixed-ratio studies for patients with massive transfusion needs. Mechanistic, logistic, and standardization concerns have been addressed and are evolving as the WB project advances. A small number of studies have been published on WB in the civilian urban trauma population. In addition, European experience with viscoelastic testing and resuscitation with fibrinogen and prothrombin complex concentrate has provided another viewpoint regarding the choice of resuscitation strategies for severely bleeding trauma patients in urban civilian environments. There are randomized controlled trials in process, which are testing the hypothesis that WB may be beneficial for the civilian urban population. Whether WB will improve mortality significantly is now a matter of intense study, and this commentary reviews the history, mechanistic foundations, and logistical aspects for the use of WB in the civilian trauma population.
Health Care Evolves From Reactive to Proactive
Waldman, Scott A. , Terzic, André

Mayo Clinic

Clinical Pharmacology & Therapeutics | December 31, 2018 | Volume: 105 | Issue: 1 | Pages: 10-13

10.1002/cpt.1295 | PMID 30597564 Get It

Guanylate cyclase-C as a therapeutic target in gastrointestinal disorders
Waldman, Scott A. , Camilleri, Michael , Waldman, Scott A

Mayo Clinic

Gut | March 21, 2018 | Volume: 67 | Issue: 8 | Pages: 1543-1552

10.1136/gutjnl-2018-316029 | PMID 29563144 Get It

Functional gastrointestinal disorders (FGIDs) and IBDs are two of the most prevalent disorders of the GI tract and consume a significant proportion of healthcare resources. Recent studies have shown that membrane-bound guanylate cyclase-C (GC-C) receptors lining the GI tract may serve as novel therapeutic targets in the treatment of FGIDs and IBDs. GC-C receptor activation by its endogenous paracrine hormones uroguanylin and guanylin, and the resulting intracellular production of its downstream effector cyclic GMP, occurs in a pH-dependent manner and modulates key physiological functions. These include fluid and electrolyte homeostasis, maintenance of the intestinal barrier, anti-inflammatory activity and regulation of epithelial regeneration. Studies of the GC-C paracrine signalling axis have revealed the therapeutic potential of these receptors in treating GI disorders, including chronic idiopathic constipation and irritable bowel syndrome–constipation. This review focuses on the evolving understanding of GC-C function in health and disease, and strategies for translating these principles into new treatments for FGIDs and IBDs.
Deep Water Running: An Effective Non-Weightbearing Exercise for the Maintenance of Land-Based Running Performance
Lauder, Tamara D., Burns, Anthony Scott

Mayo Clinic

Military Medicine | February 28, 2018 | Volume: 166 | Issue: 3 | Pages: 253-258

10.1093/milmed/166.3.253 Get It

Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea
Zhang, Wei , Mannan, Ishrat, Schulz, Stephanie, Parkinson, Scott J., Alekseev, Alexey E., Gómez, Luis Alberto , Terzic, André , Waldman, Scott A.

Mayo Clinic

The FASEB Journal | January 25, 2018 | Volume: 13 | Issue: 8 | Pages: 913-922

10.1096/fasebj.13.8.913 | PMID 10224234 Get It

ABSTRACT Bacteria that produce heat‐stable enterotoxins (STs), a leading cause of secretory diarrhea, are a major cause of morbidity and mortality worldwide. ST stimulates guanylyl cyclase C (GCC) and accumulation of intracellular cyclic GMP ([cGMP] i ), which opens the cystic fibrosis transmembrane conductance regulator (CFTR)‐related chloride channel, triggering intestinal secretion. Although the signaling cascade mediating ST‐induced diarrhea is well characterized, antisecretory therapy targeting this pathway has not been developed. 2‐ChloroATP (2ClATP) and its cell‐permeant precursor, 2‐chloroadenosine (2ClAdo), disrupt ST‐dependent signaling in intestinal cells. However, whether the ability to disrupt guanylyl cyclase signaling translates into effective antisecretory therapy remains untested. In this study, the efficacy of 2ClAdo to prevent ST‐induced water secretion by human intestinal cells was examined. In Caco‐2 human intestinal cells, ST increased [cGMP] i , induced a chloride current, and stimulated net basolateral‐to‐apical water secretion. This effect on chloride current and water secretion was mimicked by the cell‐permeant analog of cGMP, 8‐bromo‐cGMP. Treatment of Caco‐2 cells with 2ClAdo prevented ST‐induced increases in [cGMP] i , chloride current and water secretion. Inhibition of the downstream consequences of ST‐GCC interaction reflects proximal disruption of cGMP production because 8‐bromo‐cGMP stimulated chloride current and water secretion in 2ClAdo‐treated cells. Thus, this study demonstrates that disruption of guanylyl cyclase signaling is an effective strategy for antisecretory therapy and provides the basis for developing mechanism‐based treatments for enterotoxigenic diarrhea.—Zhang, W., Mannan, I., Schulz, S., Parkinson, S. J., Alekseev, A. E., Gomez, L. A., Terzic, A., Waldman, S. A. Interruption of transmembrane signaling as a novel antisecretory strategy to treat enterotoxigenic diarrhea. FASEB J. 13, 913–922 (1999)
Process Improvement for Maximized Therapeutic Innovation Outcome
Waldman, Scott A. , Terzic, André

Mayo Clinic

Clinical Pharmacology & Therapeutics | December 23, 2017 | Volume: 103 | Issue: 1 | Pages: 8-12

10.1002/cpt.929 | PMID 29265398 Get It

Deconvoluting key biological mechanisms forms the framework for therapeutic discovery. Strategies that enable effective translation of those insights along the development and regulatory path ultimately drive validated clinical application in patients and populations. Accordingly, parity in What vs. How we transform novel mechanistic insights into therapeutic paradigms is essential in achieving success. Aligning molecular discovery with innovations in structures and processes along the discovery–development–regulation–utilization continuum maximizes the return on public and private investments for next‐generation solutions in managing health and disease.
Peer Review Certifies Quality and Innovation in Clinical Pharmacology & Therapeutics
Waldman, Scott A. , Waldman, Scott A , Terzic, André

Mayo Clinic

Clinical Pharmacology & Therapeutics | August 7, 2017 | Volume: 102 | Issue: 3 | Pages: 373-377

10.1002/cpt.763 | PMID 28782825 Get It

Clinical Pharmacology & Therapeutics (CPT) is an established voice of the discipline, a trusted source of new knowledge showcasing discovery, translation, and application of novel therapeutic paradigms to advance the management of patients and populations. Identifying, evaluating, prioritizing, and disseminating the best science along the discovery–development–regulatory–utilization continuum are responsibilities shared through peer review. To enhance the uniformity of this essential component of quality assurance and innovation, and maximize the value of the journal and its contents to authors, reviewers, and the readership, we review key concepts concerning peer review as it specifically relates to CPT.